GlassScriptPhysician profile
Renzo M Corzano
NPI 1669960324
$5,290.08
in general payments reported to CMS, 2019-2025
16 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $850 · 2024: $3,392 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Travel and Lodging: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,412.08 |
| Travel and Lodging | $1,878.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,251.50 | 2024 | |
| Viiv Healthcare Company | $1,294.12 | 2023-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $510.57 | 2023-2025 | Yeztugo |
| Lilly USA, LLC | $378.14 | 2023-2025 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.40 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $152.75 | 2024-2025 | Pifeltro, Delstrigo, Dificid |
| Thd America, INC. | $112.58 | 2025 | |
| Theratechnologies INC. | $88.31 | 2024-2025 | Trogarzo, Egrifta |
| Novo Nordisk INC | $82.69 | 2023-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $32.62 | 2024-2025 | Farxiga, Wainua |
| Janssen Biotech, INC. | $29.67 | 2023 | Darzalex, Imbruvica |
| Livanova USA, INC. | $24.26 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $21.52 | 2024 | Nourianz |
| Neurocrine Biosciences, INC. | $20.91 | 2024 | Ingrezza |
| Amgen INC. | $20.45 | 2025 | Otezla, Repatha |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.59 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renzo Corzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.